Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...

Per- and polyfluoroalkyl substances (PFAS) are ubiquitous, accumulate in the environment and are difficult to break down. They are known as "forever chemicals". PFAS can compromise the immune system ...

In the United States, breast, colorectal, endometrial, pancreatic, and kidney cancers are becoming increasingly common among people under age 50, according to a new study.

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

New research disentangles the risks for acute kidney injury related to CAR T-cell treatment in non-Hodgkin lymphoma, ...

First Steps warns moviegoers to silence their cell phones, and sees H.E.R.B.I.E. speak for the first time...which isn't quite ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including ...

Antigen-presenting cells (APCs), such as dendritic cells and macrophages, are essential for initiating and regulation of anti-tumor T cell responses.

Single-cell biology has transformed how we decode cellular heterogeneity, but a new frontier is emerging: understanding what ...

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...